Trince
Kevin Braeckmans, currently a Co-founder and CSO/CTO at Trince, also serves as a Full Professor at Ghent University. With a focus on utilizing light and nanotechnology for drug delivery, Kevin is the Co-director of the Lab for General Biochemistry and Physical Pharmacy and leads the Biophotonics Research Group. Additionally, Kevin holds the position of Chairman at Ghent Light Microscopy CORE and has experience as a Guest Professor at the University of Lille. Kevin obtained a Doctor of Philosophy - PhD in Pharmaceutical Sciences from Ghent University and a Licentiate degree in Physics.
This person is not in any teams
This person is not in any offices
Trince
Trince is a spin-off company from Ghent University dedicated to advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells, both in vitro and ex vivo. The company's LumiPore transfection platform, which is covered by a portfolio of pending patents, combines laser exposure with photothermal nanoparticles to convert light energy into heat to transiently permeabilize the cellular plasma membrane. It can be used to deliver a wide variety of effector molecules (e.g. nucleic acids or proteins) into virtually any cell type, including hard-to-transfect cells such as immune cells for cell therapies. The technology not only makes it easier to bring genetic material into cells in high-throughput. It also ensures that this is done in a gentle manner, maximizing the therapeutic quality of the final cell product. www.trincebio.com